US stock results analysis for Industry - Major Pharmaceuticals for the month ending Dec 31, 2025
Analysis of which US stocks have performed the best and worst in Industry - Major Pharmaceuticals for the month ending Dec 31, 2025 on the basis of sales/revenues, profits and profit margins. Only companies which have declared results in the current month are considered.
2
POSITIVE PROFIT GROWTH
0
NEGATIVE PROFIT GROWTH
0
NEUTRAL PROFIT GROWTH
-100
%
TOTAL REVENUE GROWTH
26.9
%
TOTAL EBIDT GROWTH
36.5
%
TOTAL OPER. PROFIT GROWTH
Positive
Negative
Pending
| Stock | Last Result Updated | Market Capitalization | Current Price | Operating Revenue Qtr | Revenue Growth Qtr YoY % | Revenue Surprise Qtr % | Net Profit Qtr | Net Profit Qtr Growth YoY % | Net Profit Surprise Qtr % | Operating Profit Qtr | Operating Profit Growth Qtr YoY % | EBITDA Qtr | EBITDA Qtr growth YoY % | Operating Profit Margin Qtr % | Operating Profit Qtr Margin% YoY Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alzamend Neuro Inc | 09-Dec-2025 |
8.93
|
2.35
|
0.00
|
-
|
-
|
-1.00
|
26.50
|
-
|
-1.00
|
26.51
|
0.00
|
-24.29
|
-
|
-
|
| Lexaria Bioscience Corp | 13-Jan-2026 |
18.91
|
0.76
|
0.00
|
-100.00
|
-
|
-1.60
|
41.01
|
42.86
|
-1.57
|
41.52
|
0.00
|
-
|
-
|
-
|
